Multimedia Object Modelling and Storage Allocation Strategies for Heterogeneous Parallel Access Storage Devices in Real Time Multimedia Computing Systems

The improvements in disk speeds have not kept up with improvements in processor and memory speeds. Conventional storage techniques, in the face of multimedia data, are inefficient and/or inadequate. Here, an efficient multimedia object allocation strategy is presented. We describe a multimedia object model, the object and storage device characteristics, and the fragmentation strategy. A bipartite graph approach is used for mapping fragments to storage devices and a cost function is used to determine an efficient allocation of an object and to balance the loads on the devices

An Architecture for distributed multimedia database systems

In the past few years considerable demand for user oriented multimedia information systems has developed. These systems must provide a rich set of functionality so that new, complex, and interesting applications can be addressed. This places considerable importance on the management of diverse data types including text, images, audio and video. These requirements generate the need for a new generation of distributed heterogeneous multimedia database systems. In this paper we identify a set of functional requirements for a multimedia server considering database management, object synchronization and integration, and multimedia query processing. A generalization of the requirements to a distributed system is presented, and some of our current research and developing activities are discussed

Premessa

This volume contains the proceedings of the XIII Conference of Italian literature, held as usual at the site of the Villa Feltrinelli in Gargnano del Garda, 25 to 27 September 2008, and dedicated to Dante\u2019s Rime. Challenging topic, especially after the publication (2002) of the monumental critical edition \u2013 and then the commentary \u2013 by Domenico De Robertis, and the debate that followed. The meeting of Italian and foreign specialists gave occasion to a thorough and lively discussion, rich of new proposals on many aspects of Dante\u2019s poetry. The papers are divided, with some freedom, thematically: the first group sets the point on the correspondence between Dante and Cino, on some texts of questionable attribution and on the manuscript tradition; the second focuses on the great \u201ccanzoni\u201d and the third consists of contributions on individual poems, themes and issues of the Rime. The meeting was held as usual in a relaxed and friendly atmosphere, this year just tinged of sadness for the absence of Gennaro Barbarisi

STRATIGRAPHY, PALEOGEOGRAPHY AND GENETIC MODEL OF LATE CARNIAN CARBONATE BRECCIAS (CASTRO FORMATION, LOMBARDY, ITALY)

The stratigraphic and paleogeographic analysis of the Carnian-Norian boundary succession in central Lombardy allows the recognition of a new unit, the Castro Formation. This unit, 100-250 m thick, is represented by carbonatic intraformational breccias and associated limestones. Two lithozones have been recognized in the Castro Fm.: the lower one, heteropic with the S.Giovanni Bianco Fm., with dark dolomitic limestones and breccias intercalations, and the upper lithozone, massive, with amalgamated calcareous breccias. Microfacies, recrystallized and often tectonized, consist of mudstones, wackestones and fine packstones, locally rich in ostracods. Geochemical analyses show differences between the Castro Fm. and the overlying and underlying units, possibly because of early diagenetic meteoric imprint. The Castro Fm. depositional setting is represented by coastal ephemeral lakes with periodic emersions and erosional, tectonically controlled phenomena in a monsoonal regime

The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study

BACKGROUND: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. METHODS: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. RESULTS: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73 % of them (p < 0.0062 and <0.0082, respectively) as a consequence of the treatment. In 9 out of 19 patients a simultaneous decrease in the percentage of epithelial cells positive for CD29 and eotaxin was observed. CONCLUSION: Ketotifen besides the well-known effect in reducing signs and symptoms of AC significantly diminished production of eotaxin and expression of CD29 by epithelial cells in patients with seasonal AC

national seasonal influenza vaccination survey in europe 2008

A cross-sectional survey was undertaken with the European Union (EU) Member States and Norway and Iceland to describe seasonal influenza immunisation in the 2006-7 season, in particular to identify country-specific recommendations for risk groups, obtain vaccine uptake information and allow comparison with global recommendations. A standardised questionnaire was completed electronically by each country's project gatekeeper. Of the 29 countries surveyed, 28 recommended seasonal influenza vaccination for older age groups (22 for those aged > 65 years), and in one country vaccine was recommended for all age groups. All countries recommended vaccinating patients with chronic pulmonary and cardiovascular diseases and most countries advised to immunise patients with haematologic or metabolic disorders (n=28), immunologic disorders (n=27) and renal disease (n=27), as well as residents of long-term care facilities (n=24). Most countries recommended vaccination for staff in hospitals (n=25), long-term care facilities (n=25) and outpatient clinics (n=23), and one-third had such recommendations for workers in essential (n=10), military (n=10) and veterinary services (n=10) and poultry industry (n=13). Eight countries recommended vaccine for pregnant women; and five advised to vaccinate children (with age limits ranging from 6 months to 5 years). Twenty countries measured influenza vaccine uptake among those aged > 65 years (range 1.8%-82.1%), seven reported uptake in healthcare workers (range 14%-48%) and seven assessed coverage in persons with underlying medical conditions (range 27.6%-75.2%). The data provided by this study can assist EU states to assess and compare their influenza vaccination programme performance with other countries. The information provides a comprehensive overview of policies and programmes and their outcomes and can be used to inform joint discussions on how the national policies in the EU might be standardised in the future to achieve optimal coverage. Annual surveys could be used to monitor changes in these national policies

A narrow band neutrino beam with high precision flux measurements

The ENUBET facility is a proposed narrow band neutrino beam where lepton production is monitored at single particle level in the instrumented decay tunnel. This facility addresses simultaneously the two most important challenges for the next generation of cross section experiments: a superior control of the flux and flavor composition at source and a high level of tunability and precision in the selection of the energy of the outcoming neutrinos. We report here the latest results in the development and test of the instrumentation for the decay tunnel. Special emphasis is given to irradiation tests of the photo-sensors performed at INFN-LNL and CERN in 2017 and to the first application of polysiloxane-based scintillators in high energy physics.Comment: Poster presented at NuPhys2017 (London, 20-22 December 2017). 5 pages, 2 figure

A survey of clinical features of allergic rhinitis in adults

Background: Allergic rhinitis (AR) has high prevalence and substantial socio-economic burden. Material/Methods: The study included 35 Italian Centers recruiting an overall number of 3383 adult patients with rhinitis (48% males, 52% females, mean age 29.1, range 18–45 years). For each patient, the attending physician had to fill in a standardized questionnaire, covering, in particular, some issues such as the ARIA classification of allergic rhinitis (AR), the results of skin prick test (SPT), the kind of treatment, the response to treatment, and the satisfaction with treatment. Results: Out of the 3383 patients with rhinitis, 2788 (82.4%) had AR: 311 (11.5%) had a mild intermittent, 229 (8.8%) a mild persistent, 636 (23.5%) a moderate-severe intermittent, and 1518 (56.1%) a moderate-severe persistent form. The most frequently used drugs were oral antihistamines (77.1%) and topical corticosteroids (60.8%). The response to treatment was judged as excellent in 12.2%, good in 41.3%, fair in 31.2%, poor in 14.5%, and very bad in 0.8% of subjects. The rate of treatment dissatisfaction was significantly higher in patients with moderate-to-severe AR than in patients with mild AR (p<0.0001). Indication to allergen immunotherapy (AIT) was significantly more frequent (p<0.01) in patients with severe AR than with mild AR. . Conclusions: These fndings confirm the appropriateness of ARIA guidelines in classifying the AR patients and the association of severe symptoms with unsuccessful drug treatment. The optimal targeting of patients to be treated with AIT needs to be reassessed

Association of Accelerometry-Measured Physical Activity and Cardiovascular Events in Mobility-Limited Older Adults: The LIFE (Lifestyle Interventions and Independence for Elders) Study.

BACKGROUND:Data are sparse regarding the value of physical activity (PA) surveillance among older adults-particularly among those with mobility limitations. The objective of this study was to examine longitudinal associations between objectively measured daily PA and the incidence of cardiovascular events among older adults in the LIFE (Lifestyle Interventions and Independence for Elders) study. METHODS AND RESULTS:Cardiovascular events were adjudicated based on medical records review, and cardiovascular risk factors were controlled for in the analysis. Home-based activity data were collected by hip-worn accelerometers at baseline and at 6, 12, and 24&nbsp;months postrandomization to either a physical activity or health education intervention. LIFE study participants (n=1590; age 78.9±5.2 [SD] years; 67.2% women) at baseline had an 11% lower incidence of experiencing a subsequent cardiovascular event per 500&nbsp;steps taken per day based on activity data (hazard ratio, 0.89; 95% confidence interval, 0.84-0.96; P=0.001). At baseline, every 30&nbsp;minutes spent performing activities ≥500&nbsp;counts per minute (hazard ratio, 0.75; confidence interval, 0.65-0.89 [P=0.001]) were also associated with a lower incidence of cardiovascular events. Throughout follow-up (6, 12, and 24&nbsp;months), both the number of steps per day (per 500&nbsp;steps; hazard ratio, 0.90, confidence interval, 0.85-0.96 [P=0.001]) and duration of activity ≥500&nbsp;counts per minute (per 30&nbsp;minutes; hazard ratio, 0.76; confidence interval, 0.63-0.90 [P=0.002]) were significantly associated with lower cardiovascular event rates. CONCLUSIONS:Objective measurements of physical activity via accelerometry were associated with cardiovascular events among older adults with limited mobility (summary score &gt;10 on the Short Physical Performance Battery) both using baseline and longitudinal data. CLINICAL TRIAL REGISTRATION:URL: http://www.clinicaltrials.gov. Unique identifier: NCT01072500